Physician profile
Sherry Sinclair
NPI 1467422006
$17,167.91
in general payments reported to CMS, 2019-2025
33 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,200 · 2020: $2,542 · 2021: $2,855 · 2022: $3,067 · 2023: $1,151 · 2024: $1,633 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,404 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,404.32 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,891.82 | 2019-2025 | Krystexxa, Otezla, Evenity |
| Abbvie INC. | $2,137.13 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,601.06 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,416.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,293.92 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $1,279.39 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Horizon Therapeutics Plc | $835.05 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $780.16 | 2019-2025 | |
| Radius Health, INC. | $759.38 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $598.26 | 2019-2025 | Taltz, Zepbound, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $524.06 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $424.07 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.60 | 2019-2025 | Ofev |
| Genentech USA, INC. | $280.23 | 2019-2025 | Actemra |
| Regeneron Healthcare Solutions, INC. | $278.17 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $262.16 | 2021-2025 | Hadlima, Nexplanon |
| Celgene Corporation | $261.26 | 2019-2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $204.52 | 2019-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $189.02 | 2020-2023 | Acthar |
| Genzyme Corporation | $171.50 | 2021-2025 | |
| Boston Scientific Corporation | $167.93 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Hikma Pharmaceuticals USA | $108.57 | 2019-2021 | |
| Sobi, INC | $78.52 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $42.86 | 2019 | |
| Sandoz INC. | $40.92 | 2024-2025 | Jubbonti, Hyrimoz |
| Aurinia Pharma U.S., INC. | $39.53 | 2022-2024 | Lupkynis |
| Merck Sharp & Dohme LLC | $39.02 | 2019-2021 | |
| Almatica Pharma LLC | $36.87 | 2025 | Teriparatide |
| Bioventus LLC | $32.74 | 2020 | |
| Medexus Pharma, INC. | $23.91 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.95 | 2024 | Arcalyst |
| Zyla Life Sciences, INC. | $11.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.